In recent years PARP inhibition has emerged as a cornerstone in the maintenance treatment of advanced ovarian cancer, significantly improving outcome especially in, but not restricted to, ovarian cancers with a deficiency in homologous recombination, e.g. BRCA mutations [15]. Here, PARP1 is linked to ovarian carcinoma.